Syringic Acid for Health & Longevity - Quick Reference Sheet

Syringic Acid for Health & Longevity

Created on 07/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A plant antioxidant found in common foods such as olives, grapes, and berries. In laboratory and animal studies it calms oxidative stress and inflammation and improves blood sugar, liver, and cholesterol measures. No human studies exist, and absorption is poor. Best obtained through a plant-rich diet; isolated high-dose use is unproven with an undefined safe dose. (Full Review)

Protocol

Approach
Diet-first
Whole-food polyphenol pattern; isolated dosing unvalidated
Timing
With meals
Only reasoned timing, to coincide with post-meal glucose
Dosing
Split with meals
Logical given rapid clearance; no human regimen compared
Time to effect
In humans
Unknown
No human time-course exists
Animal markers
Days–weeks
Oxidative and metabolic markers develop over days to weeks of dosing

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Children
  • Bleeding disorders
  • Surgery within 2 weeks
Key Interactions
  • Antidiabetic drugs (insulin, sulfonylureas, metformin)
  • Antihypertensive drugs (ACE inhibitors, ARBs, calcium-channel blockers)
  • Anticoagulants/antiplatelets (warfarin, DOACs, aspirin, NSAIDs)
  • Additive metabolic supplements (berberine, cinnamon, alpha-lipoic acid, magnesium, potassium, nitrate)
  • Antioxidant stacking (polyphenols, high-dose vitamins C and E)
  • Oxidative-stress-dependent therapies (chemotherapy, radiotherapy)

Risk & Side Effects

  • High: [risks_high]
  • Medium: [risks_medium]
  • Low: Unknown human safety at supplemental doses; gastrointestinal upset
  • Speculative: Additive blood-sugar lowering; additive blood-pressure lowering; pro-oxidant effects at high concentrations; interaction with antioxidant-sensitive therapies

Monitoring

Marker Target Why
Fasting glucose 75–86 mg/dL Tracks the main proposed metabolic effect
HbA1c < 5.4% Captures 3-month average blood sugar, less noisy than a single reading
Fasting insulin 2–5 µIU/mL Detects early insulin resistance before glucose rises
Lipid panel (LDL, HDL, triglycerides) Triglycerides < 80 mg/dL; HDL > 55 mg/dL Tracks the proposed lipid effect
ALT / AST < 25 U/L (both) Watches liver, the tissue with the strongest protective signal
hs-CRP < 1.0 mg/L Tracks the general inflammation the compound is proposed to lower
Blood pressure < 120/80 mmHg Tracks the proposed blood-pressure effect and an interaction-safety signal

Cadence: Baseline before starting; re-check metabolic panel and blood pressure at 6–12 weeks, then every 6–12 months if use continues, with more frequent glucose or blood-pressure checks in the first few weeks if also on glucose- or blood-pressure-lowering medication.

Qualitative Assessment

  • Energy and perceived vitality
  • Cognitive clarity
  • Digestive comfort
  • Sleep quality